Soluble CD30 measured after lung transplantation does not predict bronchiolitis obliterans syndrome in a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen

Kwakkel-van Erp, Johanna M.; Otten, Henny G.; Paantjens, Annelieke W. M.; van Kessel, Diana A.; van Ginkel, Walter G. J.; van den Bosch, Jules M. M.; van de Graaf, Ed A.

doi:10.1016/J.HEALUN.2008.06.007

Title

Soluble CD30 measured after lung transplantation does not predict bronchiolitis obliterans syndrome in a tacrolimus/mycophenolate mofetil-based immunosuppressive regimen

Author

Kwakkel-van Erp, Johanna M.

Otten, Henny G.

Paantjens, Annelieke W. M.

van Kessel, Diana A.

van Ginkel, Walter G. J.

van den Bosch, Jules M. M.

van de Graaf, Ed A.

Abstract

Background: The purpose of this study was to determine the utility of post-transplant serum soluble CD30 levels as a biomarker for the development of the bronchiolitis obliterans syndrome (BOS) after lung transplantation during a tacrolimus/mycophenolate mofetil-based regimen. Methods: Soluble CD30 (sCD30) concentrations were measured prior to transplantation and in 175 samples taken after transplantation in 7 patients developing BOS and 7 non-BOS patients closely matched for age, underlying diseases, follow-up and gender. Results: High pre-transplant sCD30 levels dropped significantly after lung transplantation, but in the post-transplant samples no differences could be detected between patients developing BOS or not, and no changes were found prior to or during the development of BOS. Conclusions: After transplantation, sCD30 levels are consistently suppressed, but BOS is not prevented, indicating that sCD30 cannot be used as a biomarker to predict BOS after transplantation in the regimen employed.

Language

English

Source (journal)

Journal of heart and lung transplantation. - St-Louis, Mo.

Publication

St-Louis, Mo. : 2008

ISSN

1053-2498

DOI

10.1016/J.HEALUN.2008.06.007

Volume/pages

27 :10 (2008) , p. 1172-1175